

## Taisho Pharmaceutical Holdings (Japan): Stock Acquisition of Biofermin Pharmaceutical (Japan) Changes in FTSE Global Factor Index Series

19 July 2021

Taisho Pharmaceutical Holdings (Japan, constituent) has proposed to acquire Biofermin Pharmaceutical (Japan, non-constituent) through a stock transfer. According to the timetable, Biofermin Pharmaceutical will be delisted on 28 July 2021.

In order to apply index changes in a manner that can be closely replicated, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE All-World Comprehensive Factor Index	28 July 2021
FTSE Developed ex US Comprehensive Factor Index	28 July 2021
FTSE All-World ex CW Balanced Factor Index	28 July 2021
FTSE All-World ex CW Climate Balanced Factor Index	28 July 2021

Please note the share change is based on the share transfer terms of 0.5 Taisho Pharmaceutical Holdings shares for every Biofermin Pharmaceutical share held.

For further information please contact FTSE Russell Client Services at [info@ftserussell.com](mailto:info@ftserussell.com) or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at [www.ftserussell.com](http://www.ftserussell.com)

**Terms of Use** | Copyright © 2021 FTSE Russell